Data was taken from 41 healthcare systems participating in the National Patient-Centered Clinical Research Network.
Five things to know:
1. This study found monoclonal antibody treatments have been used relatively less commonly in racial and ethnic minority groups, amplifying the increased risk for severe outcomes tied to COVID-19, including death.
2. Racial and ethnic differences were smaller for inpatient administration of remdesivir and dexamethasone, which may be attributed to ease of medication access, according to the CDC.
3. The treatment disparities findings are consistent with previous study findings
4. The study didn’t identify the underlying causes for the disparities.
5. The study findings highlight disparities as a priority for intervention and can guide strategies aimed at more equitable COVID-19 outcomes.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
